Jazz Pharmaceuticals to buy GW Pharmaceuticals for $7.2bn
3rd Feb 2021 12:49
(Sharecast News) - Jazz Pharmaceuticals has agreed to buy GW Pharmaceuticals for $7.2bn.
Read moreGW Pharmaceuticals stock flies 4.8% after reporting positive test trial
26th Nov 2018 15:49
(Sharecast News) - GW Pharmaceuticals stock rose by 4.8% on Monday after it announced positive test results from new cannabis-based drug trials.
Read moreSunday newspaper round-up: Inflation, RBS, Brexit defeat, BAE Systems
12th Feb 2017 15:06
(ShareCast News) - Higher food and fuel prices drove inflation to a three-year zenith of 2% in January, up from 1.6% in December, with more increases coming as the year progresses. Figures from the Office for National Statistics are expected to confirm the jump in inflation this week, the Sunday Tel
Read moreGW Pharmaceuticals to cancel London listing, keep Nasdaq
19th Oct 2016 08:20
(ShareCast News) - GW Pharmaceuticals plans to cancel its shares from trading on AIM on 5 December, with the last day of trading on the 2nd, but will keep its listing on the Nasdaq, where most of its shares are held and traded. The biopharmaceutical company said it will continue to be headquartered
Read moreGW Pharmaceuticals nears US new drug application for epilepsy drug
26th Sep 2016 12:57
(ShareCast News) - GW Pharmaceuticals said it planned to apply to market its cannabis-derived treatment for childhood-onset epilepsy early next year after the drug produced strong results from its late-stage clinical trail. Epidiolex, the investigational cannabidiol medicine developed by GW, generat
Read moreGW Pharmaceuticals widens loss as testing ramps up
9th Aug 2016 15:25
(ShareCast News) - Cannabinoid-focused pharmaceutical company GW Pharmaceuticals posted financial results for the third quarter ended 30 June on Tuesday. The AIM-traded company reported a loss for the nine months of £46.7m, compared to £32.3m for the nine months ended 30 June 2015. It said the incr
Read moreUK GDP growth slumps to half previous rate, NIESR data shows
9th Aug 2016 12:24
(ShareCast News) - UK economic growth halved in the last three months, according to analysis by a respected independent think tank, which is worse than the market expected and adds credence to predictions that the economy will contract in the third quarter and then fall into recession. Based on its
Read moreGW Pharmaceuticals keen on $150m US offering
13th Jul 2016 15:38
(ShareCast News) - Developer of cannabinoid therapies GW Pharmaceuticals announced on Wednesday that it intends to sell, subject to market and other conditions, $150m of American Depositary Shares representing ordinary shares of GW on the NASDAQ Global Market, in an underwritten US public offering.
Read moreGW Pharma succeeds with second epilepsy trial for Epidiolex
27th Jun 2016 12:13
(ShareCast News) - GW Pharmaceuticals has revealed its cannabis-derived treatment has been found to reduce seizures for two forms of epilepsy. Phase III pivotal trials for its Epidiolex drug in the treatment of Lennox-Gastaut Syndrome, a rare and severe form of childhood-onset epilepsy, achieved the
Read moreGW to trial cannabinoid therapy on infantile spasms
21st Jun 2016 16:23
(ShareCast News) - Biopharmaceutical company GW Pharmaceuticals announced on Tuesday that it has selected infantile spasms as the fourth target indication for its Epidiolex orphan pediatric epilepsy development programme. The AIM-traded firm, which focuses on discovering, developing and commercialis
Read moreGW Pharma wins US orphan status for tuberous sclerosis complex drug
21st Apr 2016 12:16
(ShareCast News) - GW Pharmaceuticals has received 'orphan drug' designation from the US regulator for the company's cannabis-derived treatment for a rare genetic disorder. Gaining orphan status can smooth a drug's path to full approval and can entitle a drug to a seven-year exclusive marketing peri
Read moreGW Pharmaceuticals rockets on positive results for Dravet epilepsy tests
14th Mar 2016 11:33
(ShareCast News) - Shares in GW Pharmaceuticals rocketed up more than 120% after revealed exciting results of its cannabis-based treatment for children with a rare form of epilepsy. The company's first major paediatric epilepsy trial for its Epidiolex drug achieved its primary endpoint with high sta
Read moreGW Pharma losses increase ahead of key epilepsy trial results
10th Feb 2016 12:06
(ShareCast News) - Cannabis-derived medicines specialist GW Pharmaceuticals posted a £17.7m loss in the first quarter as it gears up to report data from four Phase 3 trials for its Epidiolex product. GW made £3.7m revenue in the three months to 31 December from its Sativex, less than half the £8.0m
Read moreGW Pharma surges on positive results from schizophrenia drug trial
15th Sep 2015 14:36
(ShareCast News) - Shares in GW Pharmaceuticals surged after the company announced positive top-line results from an exploratory Phase 2a placebo-controlled clinical trial of Cannabidiol (CBD) for the treatment of schizophrenia. GW said the 88 patients involved the trial had previously failed to res
Read moreGW Pharmaceuticals pre-tax loss widens on R&D costs
6th Aug 2015 13:05
(ShareCast News) - GW Pharmaceuticals posted a widening of its pre-tax loss for the nine months to the end of June as the company continues to invest heavily in its product pipeline. For the nine months ended 30 June, GW reported a pre-tax loss of $60.41m, wider than its $38.47m loss in the same per
Read more